CME: Acute Kidney Injury: Finding a Pathway to Improved Patient Outcomes

Acute Kidney Injury: Finding a Pathway to Improved Patient Outcomes

Acute Kidney Injury: Finding a Pathway to Improved Patient Outcomes
RestartResume

Since AKI occurs in 15 percent of hospitalized patients, there’s an urgent need to raise awareness of its burden on patients and healthcare systems.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Acute kidney injury (AKI) is a rapid reduction in kidney function that takes place over the course of hours or even days, and the prevalence of this condition is concerning. In fact, AKI occurs in approximately 15 percent of patients who are admitted to the hospital, with rates of AKI often surpassing 50 percent in patients receiving intensive care.

    That’s why this discussion focuses on the urgent need to raise awareness of AKI, as well as its global burden on patients and healthcare systems and ways to improve the care of patients at risk for the disease.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ravindra L. Mehta, MD
    Emeritus Professor of Medicine
    University of California San Diego Medical Center
    San Diego, CA

    Consulting Fees: AM-Pharma, bioMérieux (Astute), GE Health, Indalo, Intercept, Regulus Therapeutics
    Contracted Research: Fresenius, Fresenius Verdi, Relypsa, Inc.

    Faculty:
    Rajit K. Basu, MD, MS, FCCM
    Associate Professor of Pediatrics, Emory School of Medicine
    Research Director, Division of Pediatric Critical Care Medicine
    Children's Healthcare of Atlanta
    Atlanta, GA

    Consulting Fees: Bioporto
    Commercial Interest Speakers Bureau: Baxter

    Reviewers/Content Planners/Authors:

    • Rob Braun has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the limitations of current methods of diagnosing AKI and the ramifications of late or missed diagnosis.
    • Discuss the use of urinary biomarkers of kidney stress for early diagnosis of AKI in the critical care setting as well as tools to assess AKI risk.
  • Target Audience

    This activity is designed to meet the educational needs of Nephrologists, Critical Care Physicians, Surgeons, Emergency Medicine Physicians, Nurse Practitioners, Nurses, and Physician Assistants.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from bioMérieux.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free